Submit RFI/RFP
Request Consultation
FeaturedThe Blue Inhaler Trap: What Every Asthma Patient Should Know
Asthma Patients who rely solely on their blue inhalers may be putting their health at greater risk. That’s why The Medicines and Healthcare products Regulatory Agency (MHRA) is…
Newsroom
News
155 articles
Featured
FeaturedFirst UK Approval for Friedreich’s Ataxia Treatment
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Omaveloxolone (Skyclarys) as the first-ever treatment for Friedreich’s ataxia in patients aged 16 and older, a major…
FeaturedA New Era in Managing Thyroid Eye Disease Patients
For years now Thyroid Eye Disease (TED) has been a struggle to anyone suffering from it, with limited treatment options available on hand & sometimes the need to…
FeaturedSmarter Pathways to Biosimilars
EMA’s continuous straining efforts to develop & improve biosimilar medicine has been ongoing for decades now. While still maintaining the strict European Union safety standards with the aim…
FeaturedFezolinetant risk of liver injury: Minimizing Liver Risk with New Guidelines
Close monitoring of drugs side effects is a necessity, since leaving it un attended can lead to serious complications that on the long run maybe hear to reverse.…
FeaturedA New Chapter in Research: UK Sets Clinical Trial Standards
A new chapter in in the UK medical research has begun which is more efficient, safer & smarter. With the biggest reform in over two decades. The UK…
FeaturedEMA Endorses AI Powered Tools Supporting Liver Biopsy Analyses
As AI continues to reshape the future of healthcare, a significant milestone has been achieved. The European Medicines Agency’s (EMA) human medicines committee (CHMP) has granted the first-ever…
FeaturedRelief in Reach: New Promise to Hemophilia Warriors
For most patients suffering from a chronic illness symptoms is of course their main struggling area, but what sometimes goes un noticed is the frequency & commitment to…
FeaturedNew Approval for Hard-to-Treat HER2-Positive Cancer Tumors
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the use of trastuzumab deruxtecan (Enhertu) for treatment of people with HER-2 positive cancers that has metastasized to…
FeaturedExpanded Therapeutic use of Kaftrio & Kalydeco in cystic fibrosis patients
Based on recent studies performed by the CHMP which included clinical trials, lab tests, real world evidence studies & bibliographical data. The European Medicines Agency has recommended to…
FeaturedNew Hope for Dystrophic Epidermolysis Bullosa Patients
Dystrophic Epidermolysis Bullosa (DEB) can be a very challenging condition to live with, & with the limited treatment options available on the market, which mainly works on treating…
FeaturedFDA educational efforts prevented young people from using e-cigarettes
In a single year, FDA educational efforts prevented about 450,000 young people from beginning to use e-cigarettes According to a research co-authored by scientists from the U.S. Food…
FeaturedTriple combination medication For cystic fibrosis, deutivacaftor, tezacaftor, and vanzacaftor are approved
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the triple combination medication deutivacaftor/tezacaftor/vanzacaftor (brand name Alyftrek) to treat cystic fibrosis (CF) in individuals six years of…
FeaturedUnregulated pharmaceuticals used in advanced therapy present significant health hazards
The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) are warning the public about the risks of unregulated advanced therapy medical products (ATMPs) available to…
FeaturedmRESVIA RSV vaccine is authorized to protect individuals aged 60 and older
The Medicines and Healthcare Products Regulatory Agency (MHRA) has licensed mRNA respiratory syncytial virus (RSV) vaccine (brand name mRESVIA) to prevent individuals over the age of 60 from…
Ready to simplify your journey?
Talk to our experts and get tailored solutions to help you stay compliant and move forward with confidence.
Submit RFI/RFP